From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.
Reclassification of Hodgkin disease as Hodgkin lymphoma (HL) represents a milestone in the lymphoma field, awarding recent insights in the molecular biology of Hodgkin and Reed-Sternberg (H-RS) cells and their environment. This review summarizes antiapoptotic and proproliferative pathways involved in the pathogenesis of this disease with the ultimate goal of translating laboratory knowledge into clinical decision making. The focus is on potential targets and novel drugs, which are discussed in the context of the complex biology of HL. Considering that HL patients are more likely to die from acute and late treatment-related toxicities than from HL itself, the introduction of targeted, biologically based therapies for HL patients with palliative and eventually curative intention might be justified.
Re
Daniel
D
Department I of Internal Medicine and The Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. dre@burnham.org <dre@burnham.org>
Thomas
Roman K
RK
Behringer
Karolin
K
Diehl
Volker
V
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D002462:Cell Membrane / Q000378:metabolism; D049109:Cell Proliferation; D016207:Cytokines / Q000378:metabolism; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D007249:Inflammation; D008223:Lymphoma / Q000175:diagnosis* / Q000628:therapy*; D008954:Models, Biological; D010641:Phenotype; D016539:Reed-Sternberg Cells / Q000378:metabolism*; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D016207:Cytokines